PET and drug research and development

Journal of Nuclear Medicine

Volumn 40, Issue 7, 1999, Pages 1154-1163

  Fowler, Joanna S ^a   Volkow, Nora D ^a   Wang, Gene Jack ^a   Ding, Yu Shin ^a   Dewey, Stephen L ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

Drug development; Fluorodeoxyglucose; PET imaging

Indexed keywords

ANTINEOPLASTIC AGENT; CENTRAL NERVOUS SYSTEM AGENTS; ILLICIT DRUG; MONOAMINE OXIDASE B INHIBITOR; NEUROLEPTIC AGENT; NEW DRUG; OPIATE; PSYCHOSTIMULANT AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RADIOPHARMACEUTICAL AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADDICTION; BRAIN BLOOD FLOW; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM DISEASE; DRUG ABUSE; DRUG DEVELOPMENT; DRUG INTERACTION; DRUG MECHANISM; DRUG RESEARCH; GENE THERAPY; HUMAN; NEUTRON CAPTURE THERAPY; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

EID: 0033053187     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Fowler JS, Wolf AP, Volkow ND. New directions in positron emission tomography: part II. Annu Rep Med Chem. 1990;25:261-269.
2. Fowler JS, Volkow ND. PET imaging studies in drug abuse. J Toxicol Clin Toxicol. 1998;36:163-174.
3. Farde L. The advantage of using positron emission tomography in drug research. Trends Neurosci. 1996;19:211-214.
4. Testa B. Pharmacokinetic and pharmacodynamic events: can they always be distinguished? Trends Pharmacol Sci. 1987;8:381-383.
5. Cherry SR, Shao Y, Silverman RW, et al. MicroPET: a high-resolution PET scanner for imaging small animals. IEEE Trans Nucl Sci. 1997;44:1161-1166.
6. Gambhir SS, Barrio JR, Wu L, et al. Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J Nucl Med. 1998;39:2003-2011.
7. Tewson TJ, Krohn KA. PET radiopharmaceuticals: state-of-the-art and future prospects. Semin Nucl Med. 1998;28:221-234.
8. Volkow ND, Fowler JS, Logan J, et al. Carbon-11-cocaine binding compared at subpharmacological and pharmacological doses: a PET study. J Nucl Med. 1995;36:1289-1297.
9. Cunningham VJ, Pike VW, Bailey D, et al. A method of studying pharmacokinetics in man at picomolar drug concentrations. Br J Pharmacol. 1991;32:167-172.
10. 18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res. 1979;44:127-137.
11. 15O. II. Implementation and validation. J Nucl Med. 1983;24:790-798.
12. Bergman SR. Cardiac positron emission tomography. Semin Nucl Med. 1998;28: 320-340.
13. Volkow ND, Fowler JS, Gatley SJ, et al. PET evaluation of the dopamine system of the human brain. J Nucl Med. 1996;37:1242-1256.
14. 18F]Fluoro-dopa, an analog of dopa, and its use in direct external measurements of storage, degradation and turnover of intracerebral dopamine. Proc Natl Acad Sci USA. 1978;75:464-467.
15. Wagner HN, Burns HD, Dannals RF, et al. Imaging DA receptors in the human brain by PET. Science. 1983;221:1264-1266.
16. Farde L, Ehrin E, Eriksson L, et al. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci USA. 1985;82:3863-3867.
17. 11C]raclopride in the human brain. Synapse. 1994;16:255-262.
18. Volkow ND, Wang G-J, Fowler JS, et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature. 1997;386:830-833.
19. Fowler JS, Volkow ND, Wolf AP, et al. Mapping cocaine binding in human and baboon brain in vivo. Synapse. 1989;4:371-377.
20. Ding Y-S, Fowler JS, Volkow ND, et al. Carbon-11-d-threo-methylphenidate binding to dopamine transporter in baboon brain. J Nucl Med. 1995;36:2298-2305.
21. Madras BK, Spealman RD, Fahey MA, et al. Cocaine receptors labeled by 2-carbomethoxy-3-(4-fluorophenyl)tropane. Mol Pharmacol. 1989;36:518-524.
22. 11C]WIN 35,428. Synapse. 1993;15:130-142.
23. 11C-suicide inactivators and positron emission tomography. Science. 1987;235:481-485.
24. 11C]dihydro-tetrabenazine by dynamic PET: measurement of vesicular monoamine transporter. J Cereb Blood Flow Metab. 1996;16:1288-1299.
25. 11C-chlorpromazine in schizophrenics: positron emission tomography studies. Psychiatry Res. 1979;1:23-29.
26. 18F]haloperidol. Synapse. 1992;11:10-19.
27. 2 receptor occupancy in schizophrenic patients. Biol Psychiatry. 1988;23:653-663.
28. Wolkin A, Brodie JD, Barouche F, et al. Dopamine receptor occupancy and haloperidol levels. Arch Gen Psychiatry. 1989;46:482-483.
29. Wolkin A, Barouche F, Wolf AP, et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry. 1989;146:905-908.
30. 18F]BMY 14802, a potential antipsychotic drug. J Nucl Med. 1993;34:246-254.
31. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538-544.
32. 2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry. 1995;152:1444-1449.
33. Volkow ND, Ding Y-S, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in human brain. Arch Gen Psychiatry. 1995;52:456-463.
34. Volkow ND, Wang G-J, Fowler JS, et al. Relationship between psychostimulant induced high and dopamine transporter occupancy. Proc Natl Acad Sci USA. 1996;93:10388-10392.
35. Volkow ND, Wang G-J, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry. 1998;155:1325-1331.
36. Balster RL, Schuster CR. Fixed interval schedule of cocaine reinforcement: effect of dose and infusion duration. J Exp Anal Behav. 1973;20:119-129.
37. Volkow ND, Wang, G-J, Fowler JS, et al. Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of "high." J Pharm Exp Ther. 1999;288:14-20.
38. O'Brien CP. A range of research-based pharmacotherapies for addiction. Science. 1997;278:66-70.
39. Hamilton GS. Emerging therapeutic agents for Parkinson's disease. Chem Industry. February 16, 1998;127-132.
40. Tatton WG, Wadia JS, Ju WY, et al. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm. 1996;48(suppl):45-59.
41. DaPrada M, Kettler R, Keller HH, Burkard WP. Ro 19 6327, a reversible, highly selective inhibitor of type B monoamine oxidase, completely devoid of tyramine-potentiating effects: comparison with selegiline. In: Sandler M, Dahlstrom A, Belmaker RH, eds. Progress in Catecholamine Research. Part B: Central Aspects. New York, NY: Alan R. Liss; 1988:359-363.
42. Fowler JS, Volkow ND, Ding Y-S, Wang G-J. PET and the study of drug action in the human brain. Pharm News. 1998;5:11-16.
43. Fowler JS, Volkow ND, Logan J, et al. Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by RO 19 6327. Neurology. 1993;43:1984-1992.
44. Fowler JS, Volkow ND, Logan J, et al. Slow recovery of human brain MAO B after L-deprenyl withdrawal. Synapse. 1994;18:86-93.
45. London ED, Broussolle EPM, Links JM, et al. Morphine induced metabolic changes in human brain: studies with positron emission tomography and [fluorine-18]fluorodeoxyglucose. Arch Gen Psychiatry. 1990;47:73-81.
46. Firestone LL, Gyulai F, Mintun M, Adler LJ, Urso K, Winter PM. Human brain activity response to fentanyl imaged by positron emission tomography. Anesth Analg. 1996;82:1247-1251.
47. Jones AK, Friston KJ, Qi LY, et al. Sites of action of morphine in the brain [letter]. Lancet. 1991;338:825.
48. Kim S, Wagner HN, Villemagne VL, et al. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. J Nucl Med. 1997;38:1726-1731.
49. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med. 1991;324:384-394.
50. Gardner SF, Green JA, Bednarczyk EM, Nelson AD, Leisure G, Miraldi F. An assessment of cerebral blood flow and metabolism after fleroxacin therapy. J Clin Pharmacol. 1991;31:151-157.
51. 18F]fluoro-2-deoxy-D-glucose in the presence of ofloxacin, a gamma-aminobutyric acid and a receptor antagonist. Antimicrob Agents Chemother. 1991;35:648-652.
52. Bednarczyk EM, Green JA, Nelson AD, et al. Comparative assessment of the effect of lomefloxacin, ciprofloxacin and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by positron emission tomography. Pharmacotherapy. 1992;12:369-375.
53. Bednarczyk EM, Green JA, Nelson AD, et al. Comparison of the effect of temafloxacin, ciprofloxacin, or placebo on cerebral blood flow, glucose, and oxygen metabolism in healthy subjects by means of positron emission tomography. Clin Pharmacol Ther. 1991;50:165-171.
54. 18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography. Antimicrob Agents Chemother. 1996;40:659-664.
55. Tewson TJ, Yang D, Wong G-J, et al. The synthesis of fluorine-18 lomefloxacin and its preliminary use in human studies. Nucl Med Biol. 1996;23:767-772.
56. Volkow ND, Wang G-J, Fowler JS, et al. Enhanced sensitivity to benzodiazepines in cocaine abusers: a PET study. Am J Psychiatry. 1998;155:200-206.
57. 11C]BCNU evaluated by PET. J Nucl Med. 1986;27:775-780.
58. 13N]Cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J Nucl Med. 1987;28:1844-1852.
59. Dimitrakopoulou A, Strauss LG, Clorius JH, et al. Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma. J Nucl Med. 1993;34:1075-1081.
60. Schinkel AH, Wagenaar E, Mol CAAM, van Deemter L. P-Glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996;97:2517-2524.
61. Luker GD, Fracasso PM, Dobkin J, Piwnica Worms D. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo. J Nucl Med. 1997;38:369-372.
62. Kabalka GW, Smith GT, Kyke JP, et al. Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning. J Nucl Med. 1997;38:1762-1767.
63. Imahori Y, Ueda S, Ohmori Y, et al. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas, Part II. Clin Cancer Res. 1998;4:1833-1841.
64. Som P, Atkins HL, Bandoyapadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med. 1980;21:670-675.
65. Smith TAD. FDG uptake, tumour characteristics and response to therapy: a review. Nucl Med Commun. 1998;19:97-105.
66. 11C]glucose and FDG: analysis of the FDG lumped constant. J Nucl Med. 1998;39:440-448.
67. Warburg O. On the origin of cancer cells. Science. 1956;123:306-314.
68. Shields AF, Mankoff DA, Links JM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med. 1998;39:1757-1762.
69. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
70. 18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40:205-212.
71. 11C)-methionine in brain tumors studied with positron emission tomography. Acta Radiol. 1987;28:225-229.
72. Flanagan FL, Dehdashti F, Siegel BA. PET in breast cancer. Semin Nucl Med. 1998;28:290-302.
73. 18F]fluoro-17-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res. 1996;2:933-939.
74. 11C]PD 153035. J Labeled Compounds Radiopharm. 1997;40:377-379.
75. Mullholland GK, Zheng Q-H, Winkle WL, Carlson KA. Synthesis and biodistribution of new C-11 and F-18 labeled epidermal growth factor receptor ligands [abstract]. J Nucl Med. 1997;38:141P.
76. Prekeges JL, Rasey JS, Grunbaum Z, Krohn KH. Reduction of fluoromisonidazole: a new imaging agent for hypoxia. Biochem Pharmacol. 1991;42:2387-2395.
77. Ariens EJ. Nonchiral, homochiral and composite chiral drugs. Trends Pharmacol Sci. 1993;14:68-75.
78. 11C]d-threo and l-threo-methylphenidate in the human and baboon brain. Psychopharmacology. 1997;131:71-78.
79. Thorne RG, Emory CR, Ala TA, Frey WH II. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res. 1995;692:278-282.
80. Berridge MS, Heald DL, Muswick GJ, Liesure GP, Voelker KW, Miraldi F. Biodistribution and kinetics of nasal carbon-11-triamcinolone acetonide. J Nucl Med. 1998;39:1972-1977.
81. 11C-nicotine vapor in the human airway as visualized by positron emission tomography. Clin Pharmacol Ther. 1995;57:309-317.
82. Halpern MT, Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst. 1993;85:457-464.
83. Fowler JS, Volkow ND, Wang G-J, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA. 1996;93:14065-14069.
84. Fowler JS, Wang G-J, Volkow ND, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 1996;379:733-736.
85. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiological clue? Neurology. 1995;45:1041-1051.
86. Hughes JR, Hatsukama DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychatry. 1986;143:993-997.
87. 2 availability is associated with reduced frontal metabolism in cocaine abusers. Synapse. 1993;14:169-177.
88. Volkow ND, Wang G-J, Fowler JS, et al. Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin Exp Res. 1996;20:1594-1598.
89. Blum K, Cull JG, Braverman ER, Comings DE. Reward deficiency syndrome. Am Scientist. 1996;84:132-145.
90. 11C-raclopride and positron emission tomography. J Neurosci. 1992;12:3773-3780.
91. Dewey SL, Morgan AE, Ashby CR Jr, et al. A novel GABAergic strategy for the treatment of cocaine addiction. Synapse. 1998;30:119-129.
92. Dewey SL, Brodie JD, Gerasimov M, Horan B, Gardner EL, Ashby CR Jr. A pharmacologic strategy for the treatment of nicotine addiction. Synapse. 1999;31:76-86.
93. Brunetti A, Berg G, Di Chiro G, et al. Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3′-azido-2′,3′-dideoxythymidine (AZT, zidovudine): a PET-FDG study. J Nucl Med. 1989;30:581-590.
94. Brooks DJ. PET and SPECT studies in Parkinson's disease. Baillieres Clin Neurol. 1997;6:69-87.
95. Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci. 1996;19:102-109.
96. Larson SM, Tjuvajev J, Blasberg R. Triumph over mischance: a role for nuclear medicine in gene therapy. J Nucl Med. 1997;38:1230-1233.
97. Hnatowich DJ. Antisense and nuclear medicine. J Nucl Med. 1999;40:693-703.
98. Tjuvajev JG, Finn R, Watanabe E, et al. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res. 1996;56:4087-4095.
99. Tavitian B, Terrazzino S, Kuhnast B, et al. In vivo imaging of oligonucleotides with positron emission tomography. Nat Med. 1998;4:467-471.
100. 18F]Ro41-0960. Life Sci. 1996;58:195-208.
101. Eckelman WC. Sensitivity of new radiopharmaceuticals. Nucl Med Biol. 1998;25:169-173.
102. Pardridge WM. CNS drug design based on principles of blood-brain barrier transport. J Neurochem. 1998;70:1781-1792.